FBIO
Fortress Biotech Inc

8,963
Mkt Cap
$73.79M
Volume
295,157.00
52W High
$4.20
52W Low
$1.33
PE Ratio
-2.17
FBIO Fundamentals
Price
$2.48
Prev Close
$2.47
Open
$2.45
50D MA
$3.05
Beta
0.93
Avg. Volume
959,507.35
EPS (Annual)
-$2.69
P/B
1.68
Rev/Employee
$571,039.60
Loading...
Loading...
News
all
press releases
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -47.15% and -4.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
More News
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +62.14% and +25.22%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress...
PR Newswire·9d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress...
PR Newswire·19d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress...
PR Newswire·28d ago
News Placeholder
Why Is Fortress Biotech Stock Falling Today?
The FDA, in a letter, flagged concerns about the facility where CUTX-101 is manufactured.
Stocktwits·1mo ago
News Placeholder
Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -48.39% and +13.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +30.36% and -95.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·4mo ago

Latest FBIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.